

Primary Biliary Cirrhosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/PB4CCE22175EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PB4CCE22175EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Primary Biliary Cirrhosis - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Primary Biliary Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Primary Biliary Cirrhosis Understanding

Primary Biliary Cirrhosis: Overview

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease predominantly affecting middle-aged women. It is hypothesized that PBC begins with loss of immune self tolerance, leading to damage of the biliary epithelial cells of small bile ducts. Ongoing immunologic events perpetuate the biliary epithelial cell destruction via direct cytotoxicity or lymphokine-mediated cell damage, leading to disease progression. PBC is most commonly diagnosed after the age of 40 years. Of patients with PBC, 90% are women

'Primary Biliary Cirrhosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Primary Biliary Cirrhosis pipeline landscape is provided which includes the disease overview and Primary Biliary Cirrhosis treatment guidelines. The assessment part of the report embraces, in depth Primary Biliary Cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Biliary Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Primary Biliary Cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve Primary Biliary Cirrhosis.

Primary Biliary Cirrhosis Emerging Drugs Chapters

This segment of the Primary Biliary Cirrhosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Biliary Cirrhosis Emerging Drugs

Seladelpar: CymaBay Therapeutics

Seladelpar (MBX-8025) is a potent, selective, orally active peroxisome proliferator-activated receptor α (PPAR α) agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). Seladelpar is uniquely suited as a potential treatment for inflammatory liver diseases. In the liver, PPAR α is expressed in multiple cell types including: hepatocytes, cholangiocytes, Kupffer cells and stellate cells. Preclinical and clinical data support its effect on regulating genes involved in bile acids synthesis, inflammation, fibrosis and lipid metabolism, storage and transport. The drug is currently in phase 3 of clinical trials for the treatment of Primary

Biliary Cirrhosis.

Maralixibat: Mirum Pharmaceuticals

Maralixibat is an orally administered investigational drug being evaluated in several rare cholestatic liver diseases for both pediatric and adult populations. Maralixibat inhibits the apical sodium dependent bile acid transporter (ASBT), thereby preventing bile acids from accumulating in the liver. The drug is currently in phase 2 of clinical trials for the treatment of Primary Biliary Cirrhosis.

Further product details are provided in the report.....

Primary Biliary Cirrhosis: Therapeutic Assessment

This segment of the report provides insights about the different Primary Biliary Cirrhosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Primary Biliary Cirrhosis

There are approx. 5+ key companies which are developing the therapies for Primary Biliary Cirrhosis. The companies which have their Primary Biliary Cirrhosis drug candidates in the mid to advanced stage, i.e. phase III include, CymaBay Therapeutics and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Primary Biliary Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Biliary Cirrhosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Biliary Cirrhosis therapeutic

drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Biliary Cirrhosis drugs.

Primary Biliary Cirrhosis Report Insights

Primary Biliary Cirrhosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Primary Biliary Cirrhosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Primary Biliary Cirrhosis drugs?

How many Primary Biliary Cirrhosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Biliary Cirrhosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Biliary Cirrhosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Primary Biliary Cirrhosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

CymaBay Therapeutics

Mirum Pharmaceuticals

MYR Pharma

Incyte Corporation

Chia Tai Tianqing Pharmaceutical Group

Key Products

Seladelpar

Maralixibat

Bulevirtide

Baricitinib

TQA3526

Contents

Introduction

Executive Summary

Primary Biliary Cirrhosis: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Primary Biliary Cirrhosis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Primary Biliary Cirrhosis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Primary Biliary Cirrhosis Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Seladelpar: CymaBay Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

Maralixibat: Mirum Pharmaceuticals

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Primary Biliary Cirrhosis Key Companies

Primary Biliary Cirrhosis Key Products

Primary Biliary Cirrhosis- Unmet Needs

Primary Biliary Cirrhosis- Market Drivers and Barriers

Primary Biliary Cirrhosis- Future Perspectives and Conclusion

Primary Biliary Cirrhosis Analyst Views

Primary Biliary Cirrhosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Primary Biliary Cirrhosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Primary Biliary Cirrhosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Primary Biliary Cirrhosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PB4CCE22175EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB4CCE22175EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970